Global Crohn’s Disease Treatment Market size valued at USD 800 Mn in 2021 and expected to reach USD 1088.7 Mn by 2028, at a CAGR of 4.5% during the forecast period 2022 to 2028. Crohn’s disease belongs to a condition called inflammatory bowel disease (IBD) that causes inflammation and damage to the digestive tract. Crohn’s disease usually affects at the end of small intestine and beginning of colon, but inflammation may occur anywhere along the digestive tract. Crohn’s disease may be hereditary or develop due to the malfunctioning of the immune system. Currently there is no cure for crohn’s disease. However, there are many treatments to manage disease symptoms. Inflammation, ulcers, bowel obstruction, malnutrition, colon cancer, and anal fissures are some of the complications associated with the disease. Surgery and drug therapy are some of the treatment options available to treat Crohn’s disease. Some of the anti-inflammatory drugs used to treat crohn’s disease include, corticosteroids and oral 5-aminosalicylates. Global Crohn’s disease treatment market is expected to grow at a significant rate during the forecast period. Growth in biologics development unfolded the opportunities for the new market players as they are most commonly used in Crohn’s disease treatment. Market players are focusing on to develop new products that can treat Crohn’s disease. For instance, mongersen, is investigational therapy for the treatment of crohn’s disease, is being developed by Celgene Corporation in phase 3 clinical trials. Considering the foreseen factors Crohn’s disease treatment market is projected to have a lucrative opportunity for market players. Manufacturers of Crohn’s disease medications are concentrating on commercial distribution through retail pharmacies and online portals. Anti-inflammatory medications and corticosteroids are routinely distributed through these channels, both with and without a prescription. Consumers might also get savings when buying drugs in bulk through online platforms. The substantial rise of the anti-inflammatory medications segment of the global Crohn’s disease market is mostly due to easy product availability and price cuts.